Tryptamine and dimethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells

Cell Biochemistry and Function

Volumn 31, Issue 5, 2013, Pages 361-364

  Tourino, Melissa Cavalheiro ^a   de Oliveira, Edson Mendes ^a   Bellé, Luziane Potrich ^a   Knebel, Franciele Hinterholz ^a   Albuquerque, Renata Chaves ^a   Dörr, Felipe Augusto ^a   Okada, Sabrina Sayori ^a   Migliorini, Silene ^a   Soares, Irene Silva ^a   Campa, Ana ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Immune escape; Kynurenine pathway; Tolerance; Tryptophan metabolism; Tumor growth

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; MELATONIN; N,N DIMETHYLTRYPTAMINE; SEROTONIN; TRYPTAMINE; TRYPTOPHAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; COCULTURE; CONCENTRATION RESPONSE; CYTOTOXICITY; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MACROPHAGE; MONOCYTE; OXIDATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRYPTOPHAN METABOLISM;

IMMUNE ESCAPE; KYNURENINE PATHWAY; TOLERANCE; TRYPTOPHAN METABOLISM; TUMOR GROWTH;

BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; ENZYME ASSAYS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KINETICS; LEUKOCYTES, MONONUCLEAR; N,N-DIMETHYLTRYPTAMINE; PROTEIN BINDING; RECOMBINANT PROTEINS; TRYPTAMINES; TRYPTOPHAN;

EID: 84879842912     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2980     Document Type: Article

References (21)

1. Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity 2005; 22: 633-642.
2. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006; 29: 223-240.
3. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006; 16: 3-15.
4. Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 2006; 6: 613-625.
5. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008; 222: 206-221.
6. Hou D-Y, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007; 67: 792-801.
7. Röhring UF, Awad L, Grosdidier A, et al. Rational design of indoleamine 2, 3-dioxygenase inhibitors. J Med Chem 2010; 53: 1172-1189.
8. Friberg M, Jennings R, Alssaraj M, et al. Indoleamine 2, 3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 2002; 101: 151-155.
9. Bosch J, Roca T, Armengol M, Fernández-Forner D. Synthesis of 5-(sulfamoylmethyl)indoles. Tetrahedron 2001; 57: 1041-1048.
10. Littlejohn TK, Takikawa O, Skylas D, Jamie JF, Walker MJ, Truscott RJW. Expression and purification of recombinant human indoleamine 2, 3-dioxygenase. Protein Expr Purif 2000; 19: 22-29.
11. Boyüm A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968; 97: 77-89.
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
13. Joseph-Pietras D, Carlier A, Madoulet C, Albert P. Anti-tumoral activity of peripheral blood mononuclear cells against melanoma cells: discrepant in-vitro and in-vivo effects. Melanoma Res 2006; 16: 325-333.
14. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-271.
15. Prendergast GC. Why tumors eat tryptophan. Nature 2011; 478: 192-194.
16. Su TP, Hayashi T, Vaupel DB. When the endogenous hallucinogenic trace amine N, N-dimethyltryptamine meets the sigma-1 receptor. Sci Signal 2009; 2: pe12.
17. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature 2009; 462: 175-181.
18. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009; 323: 934-937.
19. Thompson MA, Moon E, Kim UJ, Xu JP, Siciliano MJ, Weinshilboum RM. Human indolethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization. Genomics 1999; 61: 285-297.
20. Cozzi NV, Gopalakrishnan A, Anderson LL, et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm 2009; 116: 1591-1599.
21. Vitale AA, Pomilio AB, Canellas CO, Vitale MG, Putz EM, Ciprian-Ollivier J. In vivo long-term kinetics of radiolabeled N, N-dimethyltryptamine and tryptamine. J Nucl Med 2011; 52: 970-977.